A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

NCT02872714 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

263

Enrollment

INDUSTRY

Sponsor class

Conditions

UC (Urothelial Cancer)

Interventions

DRUG: pemigatinib
DRUG: pemigatinib

Sponsor

Incyte Corporation